HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity

Hepatology

Volumn 50, Issue 1, 2009, Pages 94-101

  Gurrin, Lyle C ^a   Bertalli, Nadine A ^a   Dalton, Gregory W ^b   Osborne, Nicholas J ^a,c   Constantine, Clare C ^a,d   McLaren, Christine E ^d   English, Dallas R ^a,e   Gertig, Dorota M ^f   Delatycki, Martin B ^a,c   Nicoll, Amanda J ^g   Southey, Melissa C ^a   Hopper, John L ^a   Giles, Graham G ^e   Anderson, Gregory J ^h   Olynyk, John K ^i,j,k   Powell, Lawrie W ^h   Allen, Katrina J ^a,c,l  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Department of Human Services ^*  (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CANCER EPIDEMIOLOGY CENTRE   (Australia)

^f VICTORIAN CYTOLOGY SERVICE   (Australia)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ FREMANTLE HOSPITAL   (Australia)

^j UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^k UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^l ROYAL CHILDREN'S HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HFE PROTEIN; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC RISK; GENOTYPE; HEMOCHROMATOSIS; HETEROZYGOSITY; HUMAN; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; FOLLOW UP; GENETICS; HETEROZYGOTE; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HEMOCHROMATOSIS; HETEROZYGOTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 67651146945     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22972     Document Type: Article

References (18)

1. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004;350:2383-2397. (Pubitemid 38702849)
2. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408. (Pubitemid 26256612)
3. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221-230.
4. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769-1778. (Pubitemid 40570925)
5. Girouard J, Giguere Y, Delage R, Rousseau F. Prevalence of HFE gene C282Y and H63D mutations in a French-Canadian population of neonates and in referred patients. Hum Mol Genet 2002;11:185-189. (Pubitemid 34157010)
6. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997;34:275-278.
7. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-724. (Pubitemid 29407371)
8. Rossi E, Olynyk JK, Cullen DJ, Papadopoulos G, Bulsara M, Summerville L, et al. Compound heterozygous hemochromatosis genotype predicts increased iron and erythrocyte indices in women. Clin Chem 2000;46:162-166. (Pubitemid 30104238)
9. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-218.
10. Beutler E. Iron storage disease: facts, fiction and progress. Blood Cells Mol Dis 2007;39:140-147. (Pubitemid 47126927)
11. Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006;166:294-301.
12. Deugnier Y, Jouanolle AM, Chaperon J, Moirand R, Pithois C, Meyer JF, et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people. Br J Haematol 2002;118:1170-1178. (Pubitemid 35025987)
13. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999;130:953-962.
14. Walsh A, Dixon JL, Ramm GA, Hewett DG, Lincoln DJ, Anderson GJ, et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006;4:1403-1410. (Pubitemid 44716739)
15. Giles GG, English DR. The Melbourne Collaborative Cohort Study. IARC Sci Publ 2002;156:69-70.
16. Tavill AS. Diagnosis and management of hemochromatosis. HEPATOLOGY 2001;33:1321-1328.
17. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000;33:485-504.
18. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. HEPATOLOGY 2005;42:5-13.